palonosetron intravenous / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 72 Diseases   11 Trials   11 Trials   447 News 


12345»
  • ||||||||||  cisplatin / Generic mfg.
    Enrollment closed:  Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) -  Aug 30, 2024   
    P3,  N=72, Active, not recruiting, 
    Table: 593TiP Treatment arms ARM Drug Days ARM A (FDP-M) INJ FOSAPREPITANT 150mg IV Day1 INJ DEXAMETHASONE 8-12mg IV followed by Day1 TAB DEXAMETHASONE 4mg BD Day 1-4 INJ PALONOSETRON 0.25mg IV Day 1 TAB MIRTAZAPINE 15mg OD Day 1-4 ARM B (FDP-O) INJ FOSAPREPITANT 150mg IV Day1 INJ DEXAMETHASONE 8-12mg IV followed by Day1 TAB DEXAMETHASONE 4mg BD Day 1-4 INJ PALONOSETRON 0.25mg IV Day 1 TAB OLANZAPINE 5mg OD Day 1-4 . Recruiting --> Active, not recruiting
  • ||||||||||  cisplatin / Generic mfg.
    Phase classification, Trial completion date, Trial primary completion date:  Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) -  Nov 18, 2023   
    P3,  N=72, Recruiting, 
    Considering no hypotension occurred when using palonosetron alone, this treatment was deemed safer. Phase classification: P=N/A --> P3 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
  • ||||||||||  cisplatin / Generic mfg., palonosetron intravenous / Generic mfg.
    Journal:  Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting. (Pubmed Central) -  Mar 2, 2023   
    The achieved palonosetron blood concentrations prevented cisplatin-induced nausea and vomiting in beagle dogs. Palonosetron eye drops might provide an easy and quick method for administering palonosetron when parenteral administration is desired and intravenous administration is not feasible.
  • ||||||||||  palonosetron intravenous / Generic mfg.
    Trial completion date, Trial primary completion date:  Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC (clinicaltrials.gov) -  Jan 20, 2023   
    P3,  N=328, Recruiting, 
    Palonosetron eye drops might provide an easy and quick method for administering palonosetron when parenteral administration is desired and intravenous administration is not feasible. Trial completion date: Dec 2022 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Sep 2023
  • ||||||||||  cisplatin / Generic mfg.
    Trial completion date, Trial primary completion date:  Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) -  Nov 1, 2022   
    P=N/A,  N=72, Recruiting, 
    Trial completion date: Dec 2022 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Sep 2023 Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Sep 2023
  • ||||||||||  netupitant (Ro 67-3189) / Helsinn, Otsuka
    Management of Chemotherapy Induced Nausea and Vomiting (CINV) (RM 3(Walker Hall 1)) -  Apr 22, 2022 - Abstract #GBCC2022GBCC_98;    
    Patients scheduled to receive AC/EC were randomized 1:1 to receive FosNTP 235 mg or FosAPR 150 mg both in combination with intravenous palonosetron 0.75 mg and dexamethasone 9.9 mg on day 1... FosNTP demonstrated a favorable safety profile, with a very low risk of ISRs in the AC/EC setting.
  • ||||||||||  palonosetron intravenous / Generic mfg.
    Trial completion:  Evaluate Bioequivalence of Palonosetron (0.25mg/5mL) (clinicaltrials.gov) -  Aug 4, 2021   
    P4,  N=16, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed
  • ||||||||||  palonosetron intravenous / Generic mfg.
    Journal:  High-resolution structures of multiple 5-HTR-setron complexes reveal a novel mechanism of competitive inhibition. (Pubmed Central) -  May 15, 2021   
    Here, we present high-resolution cryo-EM structures of full-length 5-HTR in complex with palonosetron, ondansetron, and alosetron...Together with simulation results of apo- and serotonin-bound 5-HTR, the study reveals a distinct interaction fingerprint between the various setrons and binding-pocket residues that may underlie their diverse affinities. In addition, varying degrees of conformational change in the setron-5-HTR structures, throughout the channel and particularly along the channel activation pathway, suggests a novel mechanism of competitive inhibition.
  • ||||||||||  remifentanil / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Effect of Palonosetron on Remifentanil for Preventing Emergence Cough in Female (clinicaltrials.gov) -  May 10, 2021   
    P=N/A,  N=45, Completed, 
    In addition, varying degrees of conformational change in the setron-5-HTR structures, throughout the channel and particularly along the channel activation pathway, suggests a novel mechanism of competitive inhibition. Recruiting --> Completed | Trial completion date: Dec 2021 --> Mar 2021 | Trial primary completion date: Dec 2021 --> Mar 2021
  • ||||||||||  Clinical, Journal:  A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin. (Pubmed Central) -  Mar 5, 2021   
    Olanzapine is an active agent against CINV and may offer better control of nausea compared to aprepitant/fosaprepitant-based regimens...Methods We used a modified regimen "mini-OPD", oral olanzapine (5 mg) days 1 and 2, intravenous palonosetron (0.25 mg) and dexamethasone (12 mg) on day 1 of cisplatin administration in patients with carcinoma of the cervix receiving concurrent chemoradiotherapy with weekly cisplatin (40 mg/m/week)...There were no significant side effects. Conclusions The mini-OPD regimen is an inexpensive, non-toxic and effective regimen for the prevention of CINV in patients receiving weekly cisplatin concurrent with pelvic radiotherapy.
  • ||||||||||  dexamethasone / Generic mfg., palonosetron intravenous / Generic mfg.
    Observational data, Clinical Trial,Phase III, Journal, CINV:  5HT RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer. (Pubmed Central) -  Mar 2, 2021   
    Delayed chemotherapy-induced nausea and vomiting (CINV) is not well controlled in colorectal cancer (CRC) patients undergoing oxaliplatin (L-OHP)-based chemotherapy...Furthermore, whether palonosetron (PALO) or aprepitant (APR) is more effective in controlling delayed CINV is unclear...Compared to prophylactic PALO+DEX, 1st 5-HT RA+DEX+APR was more effective in controlling delayed CINV. Thus, CRC patients receiving L-OHP-based chemotherapy should be treated with three antiemetics, including APR.
  • ||||||||||  Barhemsys (intravenous amisulpride) / Acacia Pharma
    Journal:  IV Amisulpride (Barhemsys) for postoperative nausea and vomiting. (Pubmed Central) -  Jan 26, 2021   
    Adding 5 mg Olz to the steroid-sparing three-drug combination can reduce vomiting, anorexia, and fatigue, although there was no difference in CR rate. No abstract available
  • ||||||||||  remifentanil / Generic mfg.
    Enrollment open:  Effect of Palonosetron on Remifentanil for Preventing Emergence Cough in Female (clinicaltrials.gov) -  Jan 7, 2021   
    P=N/A,  N=50, Recruiting, 
    These results not only suggest that palonosetron can suppress CIN but also support the use of in silico and in vivo approaches in drug repositioning studies. Not yet recruiting --> Recruiting
  • ||||||||||  ondansetron / Generic mfg., palonosetron intravenous / Generic mfg.
    Review, Journal, CINV:  A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting. (Pubmed Central) -  Jan 6, 2021   
    Both tropisetron and palonosetron were generally well tolerated, with adverse event profiles consistent with drugs of this class (e.g., headache, constipation, and diarrhea). These data suggest that palonosetron is a highly selective prophylactic agent that may have an improved therapeutic profile compared with tropisetron, and is a feasible treatment option for controlling CINV in patients with cancer.